Last reviewed · How we verify
MMV367
At a glance
| Generic name | MMV367 |
|---|---|
| Also known as | Multiple dose |
| Sponsor | Medicines for Malaria Venture |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Phase 1b MMV367 PK/PD and Safety in Healthy Adult Volunteers Experimentally Infected With Blood Stage P. Falciparum (PHASE1)
- First-in-Human Study to Assess the Safety, Tolerability and Pharmacokinetics of MMV367 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MMV367 CI brief — competitive landscape report
- MMV367 updates RSS · CI watch RSS
- Medicines for Malaria Venture portfolio CI